WEST PHARMACEUTICAL SERVICES (WST) Stock Fundamental Analysis

NYSE:WST • US9553061055

250.49 USD
+6.88 (+2.82%)
At close: Feb 13, 2026
250.49 USD
0 (0%)
After Hours: 2/13/2026, 8:04:00 PM
Fundamental Rating

6

Taking everything into account, WST scores 6 out of 10 in our fundamental rating. WST was compared to 58 industry peers in the Life Sciences Tools & Services industry. WST scores excellent points on both the profitability and health parts. This is a solid base for a good stock. WST has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year WST was profitable.
  • In the past year WST had a positive cash flow from operations.
  • WST had positive earnings in 4 of the past 5 years.
  • WST had a positive operating cash flow in 4 of the past 5 years.
WST Yearly Net Income VS EBIT VS OCF VS FCFWST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

1.2 Ratios

  • WST has a Return On Assets of 11.98%. This is amongst the best in the industry. WST outperforms 93.10% of its industry peers.
  • WST has a Return On Equity of 16.11%. This is amongst the best in the industry. WST outperforms 87.93% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 14.78%, WST belongs to the top of the industry, outperforming 89.66% of the companies in the same industry.
  • WST had an Average Return On Invested Capital over the past 3 years of 17.99%. This is significantly above the industry average of 12.43%.
Industry RankSector Rank
ROA 11.98%
ROE 16.11%
ROIC 14.78%
ROA(3y)15.07%
ROA(5y)15.52%
ROE(3y)20.26%
ROE(5y)21.56%
ROIC(3y)17.99%
ROIC(5y)18.35%
WST Yearly ROA, ROE, ROICWST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

  • The Profit Margin of WST (16.29%) is better than 86.21% of its industry peers.
  • WST's Profit Margin has improved in the last couple of years.
  • With an excellent Operating Margin value of 20.71%, WST belongs to the best of the industry, outperforming 87.93% of the companies in the same industry.
  • WST's Operating Margin has improved in the last couple of years.
  • WST has a Gross Margin of 35.58%. This is in the lower half of the industry: WST underperforms 60.34% of its industry peers.
  • WST's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 20.71%
PM (TTM) 16.29%
GM 35.58%
OM growth 3Y-8.66%
OM growth 5Y4.7%
PM growth 3Y-10.02%
PM growth 5Y5.33%
GM growth 3Y-6.03%
GM growth 5Y0.95%
WST Yearly Profit, Operating, Gross MarginsWST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), WST is creating some value.
  • WST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
WST Yearly Shares OutstandingWST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
WST Yearly Total Debt VS Total AssetsWST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • WST has an Altman-Z score of 13.29. This indicates that WST is financially healthy and has little risk of bankruptcy at the moment.
  • WST has a Altman-Z score of 13.29. This is amongst the best in the industry. WST outperforms 98.28% of its industry peers.
  • The Debt to FCF ratio of WST is 0.55, which is an excellent value as it means it would take WST, only 0.55 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.55, WST belongs to the top of the industry, outperforming 91.38% of the companies in the same industry.
  • WST has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of WST (0.07) is better than 63.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.55
Altman-Z 13.29
ROIC/WACC1.38
WACC10.71%
WST Yearly LT Debt VS Equity VS FCFWST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

  • A Current Ratio of 2.87 indicates that WST has no problem at all paying its short term obligations.
  • WST has a Current ratio of 2.87. This is comparable to the rest of the industry: WST outperforms 50.00% of its industry peers.
  • WST has a Quick Ratio of 2.18. This indicates that WST is financially healthy and has no problem in meeting its short term obligations.
  • WST has a Quick ratio (2.18) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.18
WST Yearly Current Assets VS Current LiabilitesWST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

3

3. Growth

3.1 Past

  • WST shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 8.00%.
  • Measured over the past years, WST shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.94% on average per year.
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.51%

3.2 Future

  • WST is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.76% yearly.
  • The Revenue is expected to grow by 5.99% on average over the next years.
EPS Next Y7.67%
EPS Next 2Y10.28%
EPS Next 3Y10.83%
EPS Next 5Y10.76%
Revenue Next Year6.27%
Revenue Next 2Y6.54%
Revenue Next 3Y6.44%
Revenue Next 5Y5.99%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
WST Yearly Revenue VS EstimatesWST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
WST Yearly EPS VS EstimatesWST Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8 10

4

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 34.36, the valuation of WST can be described as expensive.
  • WST's Price/Earnings is on the same level as the industry average.
  • WST is valuated rather expensively when we compare the Price/Earnings ratio to 26.68, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 31.91, which means the current valuation is very expensive for WST.
  • 60.34% of the companies in the same industry are more expensive than WST, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of WST to the average of the S&P500 Index (28.06), we can say WST is valued inline with the index average.
Industry RankSector Rank
PE 34.36
Fwd PE 31.91
WST Price Earnings VS Forward Price EarningsWST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 63.79% of the companies in the same industry are more expensive than WST, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, WST is valued a bit cheaper than 62.07% of the companies in the same industry.
Industry RankSector Rank
P/FCF 47.53
EV/EBITDA 22.27
WST Per share dataWST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates WST does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of WST may justify a higher PE ratio.
PEG (NY)4.48
PEG (5Y)3.84
EPS Next 2Y10.28%
EPS Next 3Y10.83%

6

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.32%, WST is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.10, WST pays a better dividend. On top of this WST pays more dividend than 84.48% of the companies listed in the same industry.
  • With a Dividend Yield of 0.32, WST pays less dividend than the S&P500 average, which is at 1.84.
Industry RankSector Rank
Dividend Yield 0.32%

5.2 History

  • The dividend of WST has a limited annual growth rate of 5.90%.
  • WST has paid a dividend for at least 10 years, which is a reliable track record.
  • WST has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)5.9%
Div Incr Years32
Div Non Decr Years34
WST Yearly Dividends per shareWST Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • WST pays out 12.34% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of WST is growing, but earnings are growing more, so the dividend growth is sustainable.
DP12.34%
EPS Next 2Y10.28%
EPS Next 3Y10.83%
WST Yearly Income VS Free CF VS DividendWST Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
WST Dividend Payout.WST Dividend Payout, showing the Payout Ratio.WST Dividend Payout.PayoutRetained Earnings

WEST PHARMACEUTICAL SERVICES

NYSE:WST (2/13/2026, 8:04:00 PM)

After market: 250.49 0 (0%)

250.49

+6.88 (+2.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)04-22
Inst Owners97.92%
Inst Owner Change-89.77%
Ins Owners0.33%
Ins Owner Change0.15%
Market Cap18.02B
Revenue(TTM)N/A
Net Income(TTM)491.70M
Analysts80.87
Price Target353.41 (41.09%)
Short Float %2.68%
Short Ratio2.34
Dividend
Industry RankSector Rank
Dividend Yield 0.32%
Yearly Dividend0.81
Dividend Growth(5Y)5.9%
DP12.34%
Div Incr Years32
Div Non Decr Years34
Ex-Date01-28
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.04%
Min EPS beat(2)15.4%
Max EPS beat(2)20.68%
EPS beat(4)4
Avg EPS beat(4)14.32%
Min EPS beat(4)4.78%
Max EPS beat(4)20.68%
EPS beat(8)7
Avg EPS beat(8)11.13%
EPS beat(12)11
Avg EPS beat(12)13.12%
EPS beat(16)14
Avg EPS beat(16)10.97%
Revenue beat(2)2
Avg Revenue beat(2)2.72%
Min Revenue beat(2)1.1%
Max Revenue beat(2)4.33%
Revenue beat(4)4
Avg Revenue beat(4)1.58%
Min Revenue beat(4)0.12%
Max Revenue beat(4)4.33%
Revenue beat(8)6
Avg Revenue beat(8)0.82%
Revenue beat(12)8
Avg Revenue beat(12)1.03%
Revenue beat(16)10
Avg Revenue beat(16)0.44%
PT rev (1m)-0.18%
PT rev (3m)0.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.19%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)0.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 34.36
Fwd PE 31.91
P/S 5.97
P/FCF 47.53
P/OCF 25.97
P/B 5.91
P/tB 6.15
EV/EBITDA 22.27
EPS(TTM)7.29
EY2.91%
EPS(NY)7.85
Fwd EY3.13%
FCF(TTM)5.27
FCFY2.1%
OCF(TTM)9.64
OCFY3.85%
SpS41.95
BVpS42.42
TBVpS40.76
PEG (NY)4.48
PEG (5Y)3.84
Graham Number83.41
Profitability
Industry RankSector Rank
ROA 11.98%
ROE 16.11%
ROCE 18.01%
ROIC 14.78%
ROICexc 18.05%
ROICexgc 18.84%
OM 20.71%
PM (TTM) 16.29%
GM 35.58%
FCFM 12.56%
ROA(3y)15.07%
ROA(5y)15.52%
ROE(3y)20.26%
ROE(5y)21.56%
ROIC(3y)17.99%
ROIC(5y)18.35%
ROICexc(3y)23.92%
ROICexc(5y)24.8%
ROICexgc(3y)25.26%
ROICexgc(5y)26.44%
ROCE(3y)21.92%
ROCE(5y)22.37%
ROICexgc growth 3Y-17.09%
ROICexgc growth 5Y2.48%
ROICexc growth 3Y-16.41%
ROICexc growth 5Y3.44%
OM growth 3Y-8.66%
OM growth 5Y4.7%
PM growth 3Y-10.02%
PM growth 5Y5.33%
GM growth 3Y-6.03%
GM growth 5Y0.95%
F-Score6
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.55
Debt/EBITDA 0.26
Cap/Depr 190.61%
Cap/Sales 10.43%
Interest Coverage 250
Cash Conversion 87.8%
Profit Quality 77.1%
Current Ratio 2.87
Quick Ratio 2.18
Altman-Z 13.29
F-Score6
WACC10.71%
ROIC/WACC1.38
Cap/Depr(3y)247.41%
Cap/Depr(5y)221.86%
Cap/Sales(3y)11.72%
Cap/Sales(5y)10.45%
Profit Quality(3y)66.98%
Profit Quality(5y)67.4%
High Growth Momentum
Growth
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
EPS Next Y7.67%
EPS Next 2Y10.28%
EPS Next 3Y10.83%
EPS Next 5Y10.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.51%
Revenue Next Year6.27%
Revenue Next 2Y6.54%
Revenue Next 3Y6.44%
Revenue Next 5Y5.99%
EBIT growth 1Y6.71%
EBIT growth 3Y-8.01%
EBIT growth 5Y14.63%
EBIT Next Year37.43%
EBIT Next 3Y18.61%
EBIT Next 5Y15.79%
FCF growth 1Y-9.74%
FCF growth 3Y-5.79%
FCF growth 5Y2.8%
OCF growth 1Y-9.68%
OCF growth 3Y3.81%
OCF growth 5Y12.22%

WEST PHARMACEUTICAL SERVICES / WST FAQ

What is the fundamental rating for WST stock?

ChartMill assigns a fundamental rating of 6 / 10 to WST.


What is the valuation status for WST stock?

ChartMill assigns a valuation rating of 4 / 10 to WEST PHARMACEUTICAL SERVICES (WST). This can be considered as Fairly Valued.


Can you provide the profitability details for WEST PHARMACEUTICAL SERVICES?

WEST PHARMACEUTICAL SERVICES (WST) has a profitability rating of 8 / 10.


Can you provide the financial health for WST stock?

The financial health rating of WEST PHARMACEUTICAL SERVICES (WST) is 7 / 10.


How sustainable is the dividend of WEST PHARMACEUTICAL SERVICES (WST) stock?

The dividend rating of WEST PHARMACEUTICAL SERVICES (WST) is 6 / 10 and the dividend payout ratio is 12.34%.